Geron Corp. Upgraded to Buy by Thomson Reuters/Verus (GERN)
Geron Corp. (NASDAQ:GERN) was upgraded by analysts at Thomson Reuters/Verus from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Monday, Analyst Ratings Network reports.
Other equities research analysts have also recently issued reports about the stock. Analysts at Zacks reiterated a “neutral” rating on shares of Geron Corp. in a research note to investors on Tuesday, September 10th. They now have a $1.75 price target on the stock. Analysts at Piper Jaffray Cos. upgraded shares of Geron Corp. from a “neutral” rating to an “overweight” rating in a research note to investors on Friday, August 9th. They now have a $4.00 price target on the stock, up previously from $1.50.
Geron Corp. (NASDAQ:GERN) traded down 0.97% during mid-day trading on Monday, hitting $3.05. 650,026 shares of the company’s stock traded hands. Geron Corp. has a 52-week low of $0.91 and a 52-week high of $3.95. The stock’s 50-day moving average is $2.42 and its 200-day moving average is $1.54. The company’s market cap is $392.4 million.
Geron Corp. (NASDAQ:GERN) last released its earnings data on Thursday, August 8th. The company reported ($0.07) earnings per share for the quarter, meeting the analysts’ consensus estimate of ($0.07). The company had revenue of $0.11 million for the quarter, compared to the consensus estimate of $0.50 million. During the same quarter last year, the company posted ($0.14) earnings per share. Geron Corp.’s revenue was down 13.8% compared to the same quarter last year. On average, analysts predict that Geron Corp. will post $-0.29 earnings per share for the current fiscal year.
Geron Corporation (NASDAQ:GERN) is a biopharmaceutical company developing therapies for cancer.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.